Coca-Cola clarified that Coke Zero and Diet Coke do not contain the sugar replacement called erythritol but instead have aspartame.
According to Coca-Cola’s official website, aspartame is used in some of its products including Coke Zero Sugar, Diet Coke, Diet Coke Feisty Cherry, Diet Barq’s, Fanta Zero, Fresca, Gold Peak Diet Tea, Mello Yello Zero, Minute Maid Light, Pibb Zero, Seagrams Ginger Ale Zero Sugar, and Sprite Zero.
Aspartame provides low or no sugar calories option.
Unlike erythritol, aspartame hasn’t been linked with any serious side effects or health problems.
A recent study draws attention to the harmful effects of erythritol such as linked to causing serious health issues, including the risk of stroke, blood clotting, and heart attack
Erythritol reportedly used to “add bulk or sweeten monk fruit and keto reduced-sugar products.
According to Peace Health, one of the names for sugar alcohols used in foods labeled "sugar-free" or "no sugar added" is erythritol.
It is regarded as having calories and carbohydrates even if it is labeled as "sugar-free". It is said to have negative effects on persons who already have other underlying medical issues because it can raise blood sugar levels.
Erythritol is found naturally in some foods like wine, beer, and even cheese when they ferment.


LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal
Trump Signs Order to Cut Routine Childhood Vaccines
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
France Keeps Top Health Alert as Officials Brace for Another Heatwave
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations
Google promotes ‘teacher approved’ apps for kids. Here’s what parents should know
White House Bars CNN, MS NOW and Politico Reporters
Databricks to Invest $350 Million in Singapore AI Expansion
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



